Keytruda approved for second blood cancer
US regulators have again expanded the list of approved uses of MSD’s immunotherapy Keytruda, issuing a green light for the treatment of primary mediastinal large B-cell lymphoma (PMBCL).
Marking the drug’s second approval for a haematologic malignancy, Keytruda (pembrolizumab) can now be prescribed for patients with refractory primary forms of PMBCL, a type of non-Hodgkin lymphoma, or those who have relapsed after two or more prior lines of therapy.
The decision gives PMBCL patients access to the first anti-PD-1 therapy for their condition.
Keytruda was cleared via the US Food and Drug Administration’s accelerated pathyway on the back of data from the KEYNOTE-170 trial involving 53 patients with relapsed or refractory PMBCL.
The data showed an objective response rate (ORR) of 45 percent, with a complete response rate (CRR) of 11 percent and a partial response rate of 34 percent.
Read more: http://www.pharmatimes.com/news/keytruda_approved_for_second_blood_cancer_1240033
Marking the drug’s second approval for a haematologic malignancy, Keytruda (pembrolizumab) can now be prescribed for patients with refractory primary forms of PMBCL, a type of non-Hodgkin lymphoma, or those who have relapsed after two or more prior lines of therapy.
The decision gives PMBCL patients access to the first anti-PD-1 therapy for their condition.
Keytruda was cleared via the US Food and Drug Administration’s accelerated pathyway on the back of data from the KEYNOTE-170 trial involving 53 patients with relapsed or refractory PMBCL.
The data showed an objective response rate (ORR) of 45 percent, with a complete response rate (CRR) of 11 percent and a partial response rate of 34 percent.
Read more: http://www.pharmatimes.com/news/keytruda_approved_for_second_blood_cancer_1240033